2026 Global: Medical Devices Reimbursement Market-Competitive Review (2032) report
Description
The 2026 Global: Medical Devices Reimbursement Market-Competitive Review (2032) report features the global market size and projected growth/decline data for the period 2021 and 2032. The report primarily provides an examination of the business strategies for the ten largest global companies in the market and how their strategies differ.
Medtronic (headquartered in Dublin, Ireland), Abbott (Abbott Park, Illinois, United States), Boston Scientific (Marlborough, Massachusetts, United States), Philips (Amsterdam, Netherlands), and Stryker (Kalamazoo, Michigan, United States) are the ten major companies shaping the Medical Devices Reimbursement Market. Each firm maintains global reach, diverse device lines, and structured approaches to capture payer support. Medtronic emphasizes cardiovascular and neuromodulation products and builds value through rigorous clinical evidence, health technology assessments, and postmarket registries designed to demonstrate cost savings over time. Abbott relies on diagnostics and therapeutic devices and projects cost-effectiveness with reduced hospitalizations and improved patient outcomes, aligning payer policies through early engagement and real‑world data. Boston Scientific focuses on interventional cardiology, vascular, and rhythm management devices; it pursues coverage by aligning trials with guideline recommendations, generating real‑world evidence, and negotiating performance-based contracts in key markets. Philips, based in Amsterdam, Netherlands, integrates imaging, monitoring, and integrated care solutions; its reimbursement strategy emphasizes cross‑border economic analyses and country‑specific value dossiers to harmonize coverage decisions. Stryker, in Kalamazoo, emphasizes orthopedics and surgical navigation and champions bundled pricing, hospital‑level efficiency metrics, and long‑term cost savings shown by reduced revision rates and shortened length of stay.
Zimmer Biomet, Edwards Lifesciences, Becton Dickinson, Terumo, and Hologic — five further major players — complement this strategy with location‑specific payer engagement. Zimmer Biomet (Warsaw, Indiana, United States) markets orthopedic implants and robotics; reimbursement success depends on durability, revision risk, and total‑cost‑of‑ownership analyses that demonstrate lower lifetime costs for health systems. Edwards Lifesciences (Irvine, California, United States) specializes in structural heart disease and critical care devices; coverage decisions hinge on robust randomized data, early benefits, and guideline concordance when expanding valve and monitoring indications. Becton Dickinson (Franklin Lakes, New Jersey, United States) provides syringes, needles, and diagnostic platforms; its payer strategy emphasizes safety, infection control outcomes, and efficiencies in hospital procurement. Terumo (Tokyo, Japan) offers interventional devices, blood management, and vascular products; reimbursement focus centers on device performance, procedure safety, and cost containment across diverse health systems. Hologic (Marlborough, Massachusetts, United States) concentrates on women's health, imaging, and cancer screening; payers seek evidence that earlier detection and targeted therapies reduce downstream treatment intensity and overall costs.
Collectively, these firms drive a market in which payer ecosystems, health‑technology assessments, and real‑world evidence determine access to innovative devices. Their headquarters spread across the United States, Ireland, the Netherlands, and Japan mirrors a globalized reimbursement framework that rewards demonstrations of value, safety, and efficiency. Across regions, companies pursue comparative effectiveness research, coding and billing alignment, and value‑based agreements with health plans, hospitals, and integrated care networks; they also engage with national agencies to shape indication expansion and chronic disease management pathways. The resulting landscape supports accelerated adoption of high‑value devices while encouraging sustainable cost containment in diverse health systems worldwide today.
Medtronic (headquartered in Dublin, Ireland), Abbott (Abbott Park, Illinois, United States), Boston Scientific (Marlborough, Massachusetts, United States), Philips (Amsterdam, Netherlands), and Stryker (Kalamazoo, Michigan, United States) are the ten major companies shaping the Medical Devices Reimbursement Market. Each firm maintains global reach, diverse device lines, and structured approaches to capture payer support. Medtronic emphasizes cardiovascular and neuromodulation products and builds value through rigorous clinical evidence, health technology assessments, and postmarket registries designed to demonstrate cost savings over time. Abbott relies on diagnostics and therapeutic devices and projects cost-effectiveness with reduced hospitalizations and improved patient outcomes, aligning payer policies through early engagement and real‑world data. Boston Scientific focuses on interventional cardiology, vascular, and rhythm management devices; it pursues coverage by aligning trials with guideline recommendations, generating real‑world evidence, and negotiating performance-based contracts in key markets. Philips, based in Amsterdam, Netherlands, integrates imaging, monitoring, and integrated care solutions; its reimbursement strategy emphasizes cross‑border economic analyses and country‑specific value dossiers to harmonize coverage decisions. Stryker, in Kalamazoo, emphasizes orthopedics and surgical navigation and champions bundled pricing, hospital‑level efficiency metrics, and long‑term cost savings shown by reduced revision rates and shortened length of stay.
Zimmer Biomet, Edwards Lifesciences, Becton Dickinson, Terumo, and Hologic — five further major players — complement this strategy with location‑specific payer engagement. Zimmer Biomet (Warsaw, Indiana, United States) markets orthopedic implants and robotics; reimbursement success depends on durability, revision risk, and total‑cost‑of‑ownership analyses that demonstrate lower lifetime costs for health systems. Edwards Lifesciences (Irvine, California, United States) specializes in structural heart disease and critical care devices; coverage decisions hinge on robust randomized data, early benefits, and guideline concordance when expanding valve and monitoring indications. Becton Dickinson (Franklin Lakes, New Jersey, United States) provides syringes, needles, and diagnostic platforms; its payer strategy emphasizes safety, infection control outcomes, and efficiencies in hospital procurement. Terumo (Tokyo, Japan) offers interventional devices, blood management, and vascular products; reimbursement focus centers on device performance, procedure safety, and cost containment across diverse health systems. Hologic (Marlborough, Massachusetts, United States) concentrates on women's health, imaging, and cancer screening; payers seek evidence that earlier detection and targeted therapies reduce downstream treatment intensity and overall costs.
Collectively, these firms drive a market in which payer ecosystems, health‑technology assessments, and real‑world evidence determine access to innovative devices. Their headquarters spread across the United States, Ireland, the Netherlands, and Japan mirrors a globalized reimbursement framework that rewards demonstrations of value, safety, and efficiency. Across regions, companies pursue comparative effectiveness research, coding and billing alignment, and value‑based agreements with health plans, hospitals, and integrated care networks; they also engage with national agencies to shape indication expansion and chronic disease management pathways. The resulting landscape supports accelerated adoption of high‑value devices while encouraging sustainable cost containment in diverse health systems worldwide today.
Table of Contents
32 Pages
- 1.0 Scope of Report and Methodology
- 2.0 Market SWOT Analysis and Players
- 2.1 Market Definition
- 2.2 Market Segments
- 2.3 Market Strengths
- 2.4 Market Weaknesses
- 2.5 Market Threats
- 2.6 Market Opportunities
- 2.7 Major Players
- 3.0 Competitive Analysis
- 3.1 Market Player 1
- 3.2 Market Player 2
- 3.3 Market Player 3
- 3.4 Market Player 4
- 3.5 Market Player 5
- 3.6 Market Player 6
- 3.7 Market Player 7
- 3.8 Market Player 8
- 3.9 Market Player 9
- 3.10 Market Player 10
- 4.0 Comparative Business Strategies
- 4.1 Comparative Business Strategies of Player 1 and 2
- 4.2 Comparative Business Strategies of Player 1 and 3
- 4.3 Comparative Business Strategies of Player 1 and 4
- 4.4 Comparative Business Strategies of Player 2 and 3
- 4.5 Comparative Business Strategies of Player 2 and 4
- 4.6 Comparative Business Strategies of Player 3 and 4
- 5.0 Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
